Oral Answers to Questions

Debate between Martyn Day and Steve Baker

Wednesday 22nd March 2023 Commons Chamber

[Mr Baker]

No, not at all. I confess that I thought the hon. Lady was going to ask me about the Bill of Rights provisions in the agreement itself, but she ought to know that the parties have been working together towards that Bill of Rights and it will need consensus to deliver a framework in Northern Ireland. Of course the UK continues to be committed to the ECHR.

[Martyn Day (Linlithgow and East Falkirk) (SNP)]

7. Whether he has made a comparative assessment with Cabinet colleagues of the potential impact of the Windsor framework on economic competitiveness in (a) Northern Ireland and (b) the rest of the UK.

Oral Answers to Questions

Debate between Martyn Day and Steve Baker

Thursday 1st February 2018 Commons Chamber

[Martyn Day (Linlithgow and East Falkirk) (SNP)]

T8. The chemicals industry is the largest sectoral employer in the Grangemouth area of my constituency. It exports 60% of its goods to the EU and imports 75% of them from the EU, and it is rightly concerned about frictionless and tariff-free trade coming to an end. Will Ministers tell us what the EU exit analysis projects for that sector?

[Mr Baker]

We have met representatives of the chemicals industry on several occasions. At the most recent meeting, we had constructive conversations that ended positively. We will ensure that we carry through the positions that we have set out, particularly in relation to goods on the market, and we hope to preserve continued registration of chemicals under REACH. We will of course seek to ensure that our deep and special partnership covers the chemicals industry, so that it can flourish after we leave the EU.

Oral Answers to Questions

Debate between Martyn Day and Steve Baker

Thursday 2nd November 2017 Commons Chamber

[Mr Baker]

In due course, when we have left the European Union and we are fully free to operate our own independent trade policy, I look forward to the debates in this House on all these matters.

[Martyn Day (Linlithgow and East Falkirk) (SNP)]

4. What assessment he has made of the economic effect on Scotland in the event of the UK leaving the EU without a withdrawal agreement.

Breast Cancer Drugs

Debate between Martyn Day and Steve Baker

Thursday 26th January 2017 Commons Chamber

[Martyn Day]

I do indeed join my hon. Friend in those comments.

A new and ambitious Scottish cancer strategy, launched in 2016, aims to stop anyone dying from breast cancer by 2050, and breast cancer is of course a priority in the Scottish Government’s Detect Cancer Early initiative. We need to do many things to move forward in that direction.

No debate seems complete these days without reference to Brexit, and this issue is no exception. The Health Secretary has stated that the UK will not be in the European Medicines Agency. If so, there could be implications for the way in which medicines are regulated, and marketing authorisations will be required from the Medicines and Healthcare Products Regulatory Agency for the UK. I am in no doubt that the implications will be less efficiency and possibly longer processes for obtaining authorisations, resulting—I fear—in innovative drugs taking longer to reach patients. Some industry leaders predict delays in the region of 150 days, based on the examples of Switzerland and Canada.

According to a piece that appeared last year in the Financial Times, when Sir Michael Rawlins, chair of the MHRA, was asked whether it would be able to take on all the extra work registering new drugs and medical devices currently carried out by the EMA, he said, “Certainly not”. It seems that considerable investment and recruitment will be required to re-establish it as a stand-alone national regulator. I am keen to hear from the Minister how delayed drug access for UK patients will be avoided.

[Mr Baker]

I have listened carefully to the hon. Gentleman, and of course he raises a perfectly reasonable concern, but the campaign director of Vote Leave had, as one of his particular bugbears, the costs associated with the clinical trials directive and its prejudicial effect on innovation in medicines. I hope that the Government can find a better way through than the previous system and that, in leaving the EU, we will not only solve the problem of the EMA but have a better regulatory system afterwards.

[Martyn Day]

I thank the hon. Gentleman for his intervention, and I look forward to hearing the outcome.

In conclusion, with regards to Kadcyla, I hope the company’s resubmission to the Scottish Medicines Consortium is at a fair price to allow it to be considered for approval for use in the NHS in Scotland. It would give people across Scotland the opportunity to benefit from more treatment options and could give them precious extra time with their families and loved ones. The Scottish Government, the SMC and the NHS have worked hard to reform access to new medicines, but we now need pharmaceutical companies to do their bit by bringing forward much fairer prices for new medicines, so that access is as wide as possible for the people of Scotland. Cost-effectiveness is a key marker in ensuring that drugs are routinely available in the NHS, and I take the opportunity to emphasise that point to the pharmaceutical industry in general.